Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

and a contribution by recently-launched long-acting injectable Cabenuva (cabotegravir). On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £ ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

GSK expects 2025 sales growth between 3% and ... HIV sales increased 13%, driven by strong demand for Cabenuva and Apretude, which reached £1.3 billion in 2024. Management flagged a £150 million ...

GSK saw turnover increase by 7 per cent to £31.7billion over the full year, thanks to rising demand for specialty medicines like HIV treatments Dovato and Cabenuva and sales of oncology medicines ...